Home Equities Score In Pre-Market Session Today, Why Is The KZIA Stock Gaining Momentum?

In Pre-Market Session Today, Why Is The KZIA Stock Gaining Momentum?

Today, Kazia Therapeutics Limited (NASDAQ: KZIA) is moving higher on the charts in premarket trades. The KZIA stock is up more than 11.69% to trade at $12.42 as of the last check. Kazia Therapeutics stock closed the weekend session at $11.12 down -1.33%.

Get the hottest stocks to trade every day before the market opens 100% ‎free. Click here now. 

During the past three months, the volume of KZIA shares traded was 153.95K, which was higher than the 0.13 million shares traded in the last session. The price of Kazia stock has been rising following news of a commercialization agreement for its lead product in greater China.


3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free

Sponsored


Read More

What does the agreement cover?

Kazia Therapeutics Limited is an Australian-headquartered company that develops cancer treatments. Our leading program is paxalisib, a PI3K/Akt/mTOR inhibitor intended to treat glioblastoma, the most malignant primary brain cancer in adults. The clinical trial for paxalisib, a major advancement in the treatment of glioblastoma, began recruiting patients in January 2021.

Kazia Therapeutics today announced a licensing agreement with Simcere Pharmaceutical Group Ltd involving the development and commercialization of Kazia’s investigational new drug, paxalisib, in Greater China.

  • Mainland China, Hong Kong, Macau, and Taiwan are part of Greater China, and Simcere will be responsible for the development, registration, and commercialization of paxalisib in that region.
  • As with all other territories, Kazia retains all rights to develop and commercialize paxalisib, including in China.
  • Simcere is one of China’s fastest-growing pharmaceutical companies and has cancer, autoimmune disease, and neurological disorders its principal strategic areas of focus.
  • Paxalisib is currently the target of six additional clinical trials in other brain cancer types outside glioblastoma.

    Get the hottest stocks to trade every day before the market opens 100% ‎free. Click here now. 

What will KZIA achieve?

The deal entails Kazia Therapeutics (KZIA) receiving an upfront payment of US$ 11 million (AU$ 14.2 million), comprising US$ 7 million in cash and US$ 4 million equity capital at a premium of 20% to recent trading. Further milestones in the US$ 281 million (AU$ 362) range will be paid for indications beyond glioblastoma. A mid-teen royalty will be paid to KZIA on commercial sales by Simcere as well. Paxalisib will be developed further using transaction proceeds.

Get The Best Stocks To Trade Every Day!

Join now to get the NewsHeater.com pre-market morning brief 100% free

Must Read

IT Tech Packaging Inc. (ITP) stock gains during pre-market. Here’s what’s happening?

IT Tech Packaging Inc. (NASDAQ: ITP) stock gained by 7.53% at last close while the ITP stock price rises by 2.04% in the pre-market...

Why did The9 Limited (NCTY) stock turnaround in the after-hours on Friday?

The9 Limited (NCTY) shares gained 6.87% in after-hours on Friday, July 30, 2021, and closed the weekly trading at $11.98 per share. in the...

Energous Corporation Inc. (WATT) stock declines during after-market. Here’s to know why?

Energous Corporation Inc. (WATT) stock gained by 7.05% at last close whereas the WATT stock price plunged by 7.82% in the after-hours trading session....

AMAZON Inc. (AMZN) stock fell during after-market. Here’s the update

Amazon Inc. (NASDAQ: AMZN) stock plunged by 0.84% at last close however moving ahead the AMZAN share price also declines by 7.44% in the...

Cocrystal Pharma Inc. (COCP) stock soars during current market. Here’s what you should know

Cocrystal Pharma Inc. (NASDAQ: COCP) stock gains by 17.44% in the current market trading session. Cocrystal Pharma, Inc. is a clinical-stage biotechnology firm focused...

Best Inc. (BEST) stock gains during current market. Here’s the update?

Best Inc. (NASDAQ: BEST) stock rises by 5.45% during the current market. BEST Inc. is a prominent Chinese supplier of comprehensive smart supply chain...

Dolphin Entertainment Inc. (DLPN) stock rises during current market. Let’s find out why?

Dolphin Entertainment Inc. (NASDAQ: DLPN) stock gains by 17.47% to $9.21 today in the current market trading. Dolphin Entertainment is a leading independent entertainment...

General Electric Company Inc. (GE) stock sky-rocketing during pre-market. Here’s what you should know

General Electric Company Inc. (NASDAQ: GE) stock plunged by 2.56% at last close whereas the GE stock price surged massively during pre-market by 704.32%....

Related News

Best Inc. (BEST) stock gains during current market. Here’s the update?

Best Inc. (NASDAQ: BEST) stock rises by 5.45% during the current market. BEST Inc. is a prominent Chinese supplier of comprehensive smart supply chain...

Dolphin Entertainment Inc. (DLPN) stock rises during current market. Let’s find out why?

Dolphin Entertainment Inc. (NASDAQ: DLPN) stock gains by 17.47% to $9.21 today in the current market trading. Dolphin Entertainment is a leading independent entertainment...

CbdMD Inc. (YCBD) stock gains during after-market, given no recent update

CbdMD Inc. (NASDAQ: YCBD) stock soars by 5.43% in the after-hours trading session. CbdMD, Inc. is one of the most well-known and reputable cannabidiol...

UXIN stock declines during current market trading. What’s driving it low?

Uxin Ltd. (NASDAQ: UXIN) stock declines by 3.41% during current market trading. In China, Uxin Limited is a prominent online used vehicle dealer with...

Synthetic Biologics Inc. (SYN) stock plunged during pre-market. Here’s what you should know?

Synthetic Biologics Inc. (NASDAQ: SYN) stock gained by 8.09% at last close whereas the SYN stock price declines by 0.54% in the pre-market trading....

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Get The Best Stocks To Trade Every Day!

Join now to get the NewsHeater.com pre-market morning brief 100% free

SPECIAL GIFT

WE HAVE A GIFT FOR YOU

Download Free eBook For

7 GROWTH STOCKS FOR 2021

100% free. stop anytime no spam